EXHIBIT D



EXHIBIT D



August 29, 2003

Brigitte Groulx c/o Biochem Pharma Cancer Biology Dept. 275 Armand Frappier Laval, QC H7V 4A7 Tel: 450-978-7903

Re: U.S. Patent Application No. 08/722,659

Title: Use of Heparinase to Decrease Inflammatory

Response

Inventors: Bennett et al. Filed: September 27, 1996 Our reference No.: 104385.140

Dear Brigitte,

In furtherance of our prosecution of the above named patent, please sign the enclosed Declaration in <u>blue ink</u> and return it to me as soon as possible.

A return envelope is provided for your convenience.

If you have any questions regarding your Declaration or the present proceedings in the U.S. Patent and Trademark Office, please feel free to contact me directly at 415-884-6709 or lbjgornia@bmrn.com.

Sincerely,

Luisa Bigornía Ph.D., Esq.



1108 256 614 AA1 26:11 4002/61/LU

Attorney Docket No. 104385.140

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
BENNETT et al.) Group Art Unit: 1644
)
Serial No.: 08/722,659) Examiner: A. DeCloux
)
Filed: September 27, 1996)
•)
For: USE OF HEPARINASE TO DECI	REASE INFLAMMATORY RESPONSE

Commissioner for Patents Washington, D.C. 20231

DECLARATION UNDER 37 C.F.R. § 1.132 OF DOMINIQUE FINK

- I, Dominique Fink, do hereby declare that:
- 1. I am a joint inventor of the subject matter claimed in the above-identified application, along with Elizabeth Cauchon, Brigette Grouix, Ariane Hsia, Joseph Zimmermann, D. Clark Bennett, and Pamela Danagher.
- 2 I am informed and believe that U.S. Patent No. 5,997,863 ("the'863 patent"), a copy of which is attached as Exhibit A, has been cited against the claims of the above-identified application. In particular, I am informed and believe that Example 8 found at col. 17, line 63col. 18, line 29 has been cited against the above-captioned application in a prior art rejection.
- 3. While I am a co-inventor of the above-captioned application, I did not make an inventive contribution to the subject matter recited in paragraph 2. In particular, I was not involved in the animal model work described in Example 8 involving the local administration of heparinase to enhance revascularization, described generally at col. 17, line 63-col. 18, line 29.
 - 4. The undersigned declares further that all statements made herein of my own

Signed at	
this day of, 2003.	Dominique Fink

Attorney Docket No. 104385.140

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re A	application of:)	
	BENNETT et al.) (Group Art Unit: 1644
)	-
Serial :	No.: 08/722,659) I	Examiner: A. DeCloux
)	
Filed:	September 27, 1996)	•
_)	
For:	USE OF REPARINASE TO DECRE	ASE IN	FLAMMATORY RESPONSE

Commissioner for Patents Washington, D.C. 20231

DECLARATION UNDER 37 C.F.R. § 1.132 OF BRIGETTE GROUIX

I, Brigette Grouix, do hereby declare that:

- I am a joint inventor of the subject matter claimed in the above-identified application, along with Elizabeth Cauchon, Dominique Fink, Ariane Haia, Joseph Zimmermann,
 Clark Bennett, and Pamela Danagher.
- 2. I am informed and believe that U.S. Patent No. 5,997,863 ("the'863 patent"), a copy of which is attached as Exhibit A, has been cited against the claims of the above-identified application. In particular, I am informed and believe that Example 8 found at col. 17, line 63-col. 18, line 29 has been cited against the above-captioned application in a prior art rejection.
- 3. While I am a co-inventor of the above-captioned application, I did not make an inventive contribution to the subject matter recited in paragraph 2. In particular, I was not involved in the animal model work described in Example 8 involving the local administration of heparinase to enhance revascularization, described generally at col. 17, line 63-col. 18, line 29.
 - 4. The undersigned declares further that all statements made herein of my own

Signed a	ıt		
•			Brigette Grouix
this de	av of	. 2003.	



August 29, 2003

Ariane Hsia c/o RIV LTD. 22 Wesllesley St. East Toronto, Ontario M4Y 1Y3

Re: U.S. Patent Application No. 08/722,659

Title: Use of Heparinase to Decrease Inflammatory

Response

inventors: Bennett *et al.*Filed: September 27, 1996
Our reference No.: 104385,140

Dear Ariane.

In furtherance of our prosecution of the above named patent, please sign the enclosed Declaration in <u>blue ink</u> and return it to me as soon as possible.

A return envelope is provided for your convenience.

If you have any questions regarding your Declaration or the present proceedings in the U.S. Patent and Trademark Office, please feel free to contact me directly at 415-884-6709 or lbigornia@bmrn.com,

Sincerely,

Luisa Bigornía Ph.D., Esq.

LSB/rvc



Attorney Docket No. 104385.140

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re A	Application of:)
	BENNETT et al.) Group Art Unit: 1644)
Serial	No.: 08/722,659) Examiner: A. DeCloux
Filed:	September 27, 1996))
For:	USE OF HEPARINASE TO DECRE	ASE INFLAMMATORY RESPONSE
a	Section of Posts 4	

Commissioner for Patents Washington, D.C. 20231

DECLARATION UNDER 37 C.F.R. § 1.132 OF ARIANE HSIA

- I, Ariane Hsia, do hereby declare that:
- I am a joint inventor of the subject matter claimed in the above-identified application, along with Elizabeth Cauchon, Dominique Fink, Brigette Grouix, Joseph Zimmermann, D. Clark Bennett, and Pamela Danagher.
- 2. I am informed and believe that U.S. Patent No. 5,997,863 ("the'863 patent"), a copy of which is attached as Exhibit A, has been cited against the claims of the above-identified application. In particular, I am informed and believe that Example 8 found at col. 17, line 63-col. 18, line 29 has been cited against the above-captioned application in a prior art rejection.
- 3. While I am a co-inventor of the above-captioned application, I did not make an inventive contribution to the subject matter recited in paragraph 2. In particular, I was not involved in the animal model work described in Example 8 involving the local administration of heparinase to enhance revascularization, described generally at col. 17, line 63-col. 18, line 29.
 - 4. The undersigned declares further that all statements made herein of my own

Signed at	
	Ariane Hsia
this day of, 2003.	



August 29, 2003

Ms. Dominique Fink 4632 rue Chambord Montreal, Quebec H2J 3M7

Re: U.S. Patent Application No. 08/722,659
Title: Use of Heparinase to Decrease Inflammatory

Response

Inventors: Bennett *et al.*Filed: September 27, 1996
Our reference No.: 104385.140

Dear Ms. Fink,

In furtherance of our prosecution of the above named patent, please sign the enclosed Declaration in <u>blue ink</u> and return it to me as soon as possible.

A return envelope is provided for your convenience.

If you have any questions regarding your Declaration or the present proceedings in the U.S. Patent and Trademark Office, please feel free to contact me directly at 415-884-6709 or lbjgornia@bmrn.com.

Sincerely.

Luisa Bigornia Ph.D., Esq.

LSB/IVC



Attorney Docket No. 104385.140

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: BENNETT et al.) Group Art Unit: 1644
Serial No.: 08/722,659) Rxaminer: A. DeCloux
Filed: September 27, 1996	,)
For: USE OF HEPARINASE TO DECRE) ASE INFLAMMATORY RESPONSE

Commissioner for Patents Washington, D.C. 20231

DECLARATION UNDER 37 C.F.R. § 1.132 OF DOMINIQUE FINK

- I, Dominique Fink, do hereby declare that:
- I am a joint inventor of the subject matter claimed in the above-identified application, along with Elizabeth Cauchon, Brigette Grouix, Ariane Hsia, Joseph Zimmermann,
 Clark Bennett, and Pamela Danagher.
- 2. I am informed and believe that U.S. Patent No. 5,997,863 ("the 863 patent"), a copy of which is attached as Exhibit A, has been cited against the claims of the above-identified application. In particular, I am informed and believe that Example 8 found at col. 17, line 63-col. 18, line 29 has been cited against the above-captioned application in a prior art rejection.
- 3. While I am a co-inventor of the above-captioned application, I did not make an inventive contribution to the subject matter recited in paragraph 2. In particular, I was not involved in the animal model work described in Example 8 involving the local administration of heparinase to enhance revascularization, described generally at col. 17, line 63-col. 18, line 29.
 - The undersigned declares further that all statements made herein of my own



Signed at		Dominique Fink
this _ day of 2003.	•	DOWNTEN TO THE

